Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | POLA1 | P09884 | 1/20 | 0.50 |
| ▸ | POLG | P54098 | 1/20 | 0.50 |
| ▸ | HPRT1 | P00492 | 11/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PNP | P00491 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22504363 | 0.93 | POLB (0.53) | POLBPOLA1POLGHPRT1MEN1 | |
| SCHEMBL2734853 | 0.88 | POLB (0.57) | POLBPOLA1POLGHPRT1MEN1 | |
| SCHEMBL17617326 | 0.88 | POLB (0.57) | POLBPOLA1POLGHPRT1MEN1 | |
| SCHEMBL17617327 | 0.88 | POLB (0.51) | POLBPOLA1POLGHPRT1MEN1 | |
| SCHEMBL17617645 | 0.88 | POLB (0.51) | POLBPOLA1POLGHPRT1MEN1 | |
| SCHEMBL17622434 | 0.86 | POLB (0.55) | POLBPOLA1POLGHPRT1MEN1 | |
| SCHEMBL17621846 | 0.86 | POLB (0.55) | POLBPOLA1POLGHPRT1MEN1 | |
| SCHEMBL17621845 | 0.86 | POLB (0.55) | POLBPOLA1POLGHPRT1MEN1 | |
| SCHEMBL17622435 | 0.86 | POLB (0.55) | POLBPOLA1POLGHPRT1MEN1 | |
| SCHEMBL19770626 | 0.84 | POLB (0.53) | POLBPOLA1POLGHPRT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11344555-B2 | Nucleotide analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-31 | — | — | US | disclosed |
| US-20200316076-A1 | Nucleotide Analogs | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200316076-A1 | Nucleotide Analogs | NUDT1, DUT, DPYD | POLB 29/4885POLA1 97/4885POLG 120/4885 |
| US-11344555-B2 | Nucleotide analogs | NUDT1, DUT, DPYD | POLB 29/4885POLA1 97/4885POLG 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.